Literature DB >> 24067262

Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index.

Stergios A Polyzos1, Jannis Kountouras, Athanasios Papatheodorou, Evangelia Katsiki, Kalliopi Patsiaoura, Efthimia Zafeiriadou, Evridiki Papadopoulou, Christos Zavos, Evangelos Terpos.   

Abstract

BACKGROUND AND RATIONALE: Insulin resistance (IR), adipocytokines, oxidative stress and hepatic apoptosis play a pathogenetic role in nonalcoholic fatty liver disease (NAFLD). AIMS: The evaluation of specific adipocytokines and markers of IR, oxidative stress and apoptosis in NAFLD patients; the introduction of a combined non-invasive index for nonalcoholic steatohepatitis (NASH).
MATERIAL AND METHODS: Thirty patients with biopsy-proven NAFLD (15 with simple nonalcoholic fatty liver [NAFL], 15 with NASH) and 24 controls were recruited. Blood samples for total and high molecular weight (HMW) adiponectin, visfatin and tumor necrosis factor (TNF)-α, the apoptotic by-product cytokeratin (CK)-18, the reactive oxygen metabolites (ROMs) and standard biochemical tests were measured. Homeostatic model of assessment - insulin resistance (HOMA-IR) and quantitative insulin sensitivity check index (QUICKI) were calculated. MAIN
RESULTS: Total and HMW adiponectin were significantly lower and TNF-α higher in either NAFL or NASH group compared to control group; CK-18 was significantly higher in NASH compared to either NAFL or control group. CHAI (an acronym of CK-18, HOMA-IR, AST Index) was calculated as the product of parameters being significantly different between NAFL and NASH groups. CHAI was significantly higher in NASH (24.2 [15.1-214.0]) compared to either NAFL (15.7 [6.8-22.7]) or control (5.1 [2.4-7.6]) group (p < 0.001) and significantly higher as the severity of steatosis, fibrosis, ballooning, lobular and portal inflammation advanced.
CONCLUSION: CHAI was escalating from controls to NAFL and NASH and was higher by increasing the severity of all the main histological lesions. However, a validation study is needed before introducing CHAI in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24067262

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  8 in total

1.  Circulating periostin in patients with nonalcoholic fatty liver disease.

Authors:  Stergios A Polyzos; Jannis Kountouras; Athanasios D Anastasilakis; Athanasios Papatheodorou; Panagiotis Kokkoris; Evangelos Terpos
Journal:  Endocrine       Date:  2016-10-13       Impact factor: 3.633

2.  Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD.

Authors:  Stergios A Polyzos; Nikolaos Perakakis; Chrysoula Boutari; Jannis Kountouras; Wael Ghaly; Athanasios D Anastasilakis; Asterios Karagiannis; Christos S Mantzoros
Journal:  J Clin Endocrinol Metab       Date:  2020-03-01       Impact factor: 5.958

Review 3.  Lipotoxicity as the Leading Cause of Non-Alcoholic Steatohepatitis.

Authors:  Marija Branković; Igor Jovanović; Marija Dukić; Tijana Radonjić; Svetlana Oprić; Slobodan Klašnja; Marija Zdravković
Journal:  Int J Mol Sci       Date:  2022-05-05       Impact factor: 6.208

Review 4.  NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential.

Authors:  Na Xie; Lu Zhang; Wei Gao; Canhua Huang; Peter Ernst Huber; Xiaobo Zhou; Changlong Li; Guobo Shen; Bingwen Zou
Journal:  Signal Transduct Target Ther       Date:  2020-10-07

Review 5.  Targeting programmed cell death in metabolic dysfunction-associated fatty liver disease (MAFLD): a promising new therapy.

Authors:  Jianan Zhao; Yiyang Hu; Jinghua Peng
Journal:  Cell Mol Biol Lett       Date:  2021-05-07       Impact factor: 5.787

6.  Effect of glucagon-like peptide-1 receptor agonists on adipokine level of nonalcoholic fatty liver disease in rats fed high-fat diet.

Authors:  Miaomiao Jin; Xiaohong Niu; Yan Liu; Dong Zhang; Danni Yuan; Huimin Shen
Journal:  Open Med (Wars)       Date:  2020-07-18

Review 7.  Adipokines in Non-Alcoholic Fatty Liver Disease: Are We on the Road toward New Biomarkers and Therapeutic Targets?

Authors:  Vera Francisco; Maria Jesus Sanz; José T Real; Patrice Marques; Maurizio Capuozzo; Djedjiga Ait Eldjoudi; Oreste Gualillo
Journal:  Biology (Basel)       Date:  2022-08-19

Review 8.  Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease.

Authors:  Chrysoula Boutari; Nikolaos Perakakis; Christos Socrates Mantzoros
Journal:  Endocrinol Metab (Seoul)       Date:  2018-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.